Eribulin-A review of preclinical and clinical studies

Umang Swami, Imran Chaudhary, Mohammad H. Ghalib, Sanjay Goel

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Eribulin mesylate is a non-taxane, structurally simplified, completely synthetic, halichondrin B derivative with an end poisoning, microtubule inhibitory action. Preclinical studies have demonstrated activity in various cancer cell lines and synergistic action with gemcitabine, epirubicin, trastuzumab, cisplatin, docetaxel and vinorelbine. Eribulin has recently been approved by United States Food and Drug Administration as a third line therapy for metastatic breast cancer patients, who have previously been treated with an anthracycline and a taxane. It has also advanced to phase II trials in non-small cell lung cancer, pancreatic, prostate, bladder, head and neck cancers, sarcomas and ovarian and other gynecological tumors. Combination trials with carboplatin, gemcitabine, pemetrexed, cisplatin, and erlotinib are currently ongoing. Eribulin potentially has a low incidence of peripheral neuropathy. The predominant side effects are neutropenia and fatigue, which are manageable. This article reviews the available information on eribulin with respect to its clinical pharmacology, mechanism of action, pharmacokinetics, pharmacodynamics, metabolism, preclinical studies and clinical trials.

Original languageEnglish (US)
Pages (from-to)163-184
Number of pages22
JournalCritical Reviews in Oncology/Hematology
Volume81
Issue number2
DOIs
StatePublished - Feb 2012

Fingerprint

eribulin
gemcitabine
docetaxel
Cisplatin
Pemetrexed
Prostatic Neoplasms
Epirubicin
Clinical Pharmacology
Anthracyclines
Carboplatin
Peripheral Nervous System Diseases
United States Food and Drug Administration
Head and Neck Neoplasms
Neutropenia
Pancreatic Neoplasms
Urinary Bladder Neoplasms
Non-Small Cell Lung Carcinoma
Microtubules
Sarcoma
Poisoning

Keywords

  • Breast cancer
  • E7389
  • EMBRACE
  • Eribulin
  • Halaven™
  • Halichondrin B
  • Microtubule inhibitor
  • NSC 707389

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Cite this

Eribulin-A review of preclinical and clinical studies. / Swami, Umang; Chaudhary, Imran; Ghalib, Mohammad H.; Goel, Sanjay.

In: Critical Reviews in Oncology/Hematology, Vol. 81, No. 2, 02.2012, p. 163-184.

Research output: Contribution to journalArticle

Swami, Umang ; Chaudhary, Imran ; Ghalib, Mohammad H. ; Goel, Sanjay. / Eribulin-A review of preclinical and clinical studies. In: Critical Reviews in Oncology/Hematology. 2012 ; Vol. 81, No. 2. pp. 163-184.
@article{4bf6121990634dfeb691a6f4298d9657,
title = "Eribulin-A review of preclinical and clinical studies",
abstract = "Eribulin mesylate is a non-taxane, structurally simplified, completely synthetic, halichondrin B derivative with an end poisoning, microtubule inhibitory action. Preclinical studies have demonstrated activity in various cancer cell lines and synergistic action with gemcitabine, epirubicin, trastuzumab, cisplatin, docetaxel and vinorelbine. Eribulin has recently been approved by United States Food and Drug Administration as a third line therapy for metastatic breast cancer patients, who have previously been treated with an anthracycline and a taxane. It has also advanced to phase II trials in non-small cell lung cancer, pancreatic, prostate, bladder, head and neck cancers, sarcomas and ovarian and other gynecological tumors. Combination trials with carboplatin, gemcitabine, pemetrexed, cisplatin, and erlotinib are currently ongoing. Eribulin potentially has a low incidence of peripheral neuropathy. The predominant side effects are neutropenia and fatigue, which are manageable. This article reviews the available information on eribulin with respect to its clinical pharmacology, mechanism of action, pharmacokinetics, pharmacodynamics, metabolism, preclinical studies and clinical trials.",
keywords = "Breast cancer, E7389, EMBRACE, Eribulin, Halaven™, Halichondrin B, Microtubule inhibitor, NSC 707389",
author = "Umang Swami and Imran Chaudhary and Ghalib, {Mohammad H.} and Sanjay Goel",
year = "2012",
month = "2",
doi = "10.1016/j.critrevonc.2011.03.002",
language = "English (US)",
volume = "81",
pages = "163--184",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Eribulin-A review of preclinical and clinical studies

AU - Swami, Umang

AU - Chaudhary, Imran

AU - Ghalib, Mohammad H.

AU - Goel, Sanjay

PY - 2012/2

Y1 - 2012/2

N2 - Eribulin mesylate is a non-taxane, structurally simplified, completely synthetic, halichondrin B derivative with an end poisoning, microtubule inhibitory action. Preclinical studies have demonstrated activity in various cancer cell lines and synergistic action with gemcitabine, epirubicin, trastuzumab, cisplatin, docetaxel and vinorelbine. Eribulin has recently been approved by United States Food and Drug Administration as a third line therapy for metastatic breast cancer patients, who have previously been treated with an anthracycline and a taxane. It has also advanced to phase II trials in non-small cell lung cancer, pancreatic, prostate, bladder, head and neck cancers, sarcomas and ovarian and other gynecological tumors. Combination trials with carboplatin, gemcitabine, pemetrexed, cisplatin, and erlotinib are currently ongoing. Eribulin potentially has a low incidence of peripheral neuropathy. The predominant side effects are neutropenia and fatigue, which are manageable. This article reviews the available information on eribulin with respect to its clinical pharmacology, mechanism of action, pharmacokinetics, pharmacodynamics, metabolism, preclinical studies and clinical trials.

AB - Eribulin mesylate is a non-taxane, structurally simplified, completely synthetic, halichondrin B derivative with an end poisoning, microtubule inhibitory action. Preclinical studies have demonstrated activity in various cancer cell lines and synergistic action with gemcitabine, epirubicin, trastuzumab, cisplatin, docetaxel and vinorelbine. Eribulin has recently been approved by United States Food and Drug Administration as a third line therapy for metastatic breast cancer patients, who have previously been treated with an anthracycline and a taxane. It has also advanced to phase II trials in non-small cell lung cancer, pancreatic, prostate, bladder, head and neck cancers, sarcomas and ovarian and other gynecological tumors. Combination trials with carboplatin, gemcitabine, pemetrexed, cisplatin, and erlotinib are currently ongoing. Eribulin potentially has a low incidence of peripheral neuropathy. The predominant side effects are neutropenia and fatigue, which are manageable. This article reviews the available information on eribulin with respect to its clinical pharmacology, mechanism of action, pharmacokinetics, pharmacodynamics, metabolism, preclinical studies and clinical trials.

KW - Breast cancer

KW - E7389

KW - EMBRACE

KW - Eribulin

KW - Halaven™

KW - Halichondrin B

KW - Microtubule inhibitor

KW - NSC 707389

UR - http://www.scopus.com/inward/record.url?scp=84856235418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856235418&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2011.03.002

DO - 10.1016/j.critrevonc.2011.03.002

M3 - Article

C2 - 21493087

AN - SCOPUS:84856235418

VL - 81

SP - 163

EP - 184

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 2

ER -